Charrat, Switzerland

Pierre-Michel Regenass

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Debiopharm International, S.a.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre-Michel Regenass. Retrieved from https://idiyas.com/inventor/pierre-michel-regenass

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Pierre-Michel Regenass: Innovator in Antibiotic Compounds

Introduction: Pierre-Michel Regenass is an inventor based in Charrat, Switzerland. He is currently associated with Debiopharm International, S.A., where he contributes to the development of innovative pharmaceutical solutions. Although he does not hold any granted patents, his work in the field of antibiotic compounds is noteworthy.

Latest Patent Applications: Pierre-Michel Regenass has submitted several patent applications, including "Antibiotic Compounds, Methods of Manufacturing the Same, Pharmaceutical Compositions Containing the Same and Uses Thereof." This invention provides compounds suitable for treating infections and related conditions. Another significant application is "Condensed Pyrroles as Novel Bromodomain Inhibitors," which involves compounds that may be used in the treatment of diseases requiring bromodomain inhibition.

Conclusion: Pierre-Michel Regenass is a dedicated inventor focused on advancing antibiotic treatments through his innovative applications. His contributions to the pharmaceutical industry reflect a commitment to improving healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…